Inactive Instrument

News Kawasumi Laboratories, Incorporated

Stocks

7703

JP3225800006

Medical Equipment, Supplies & Distribution

All News

06/02/20	Kawasumi Laboratories, Incorporated Reports Consolidated Earnings Results for Nine Months Ended December 31, 2019; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2020	CI
08/11/19	Kawasumi Laboratories, Incorporated Announces Consolidated Earnings Results for the Six Months Ended September 30, 2019; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2020; Announces Dividend for the Second Quarter Ended September 30, 2019, Payable on December 2, 2019; Provides Year End Dividend Guidance for the Year Ending March 31, 2020	CI
08/08/19	Kawasumi Laboratories, Incorporated Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2019; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2020; Provides Dividend Guidance for the Second Quarter of Fiscal 2020 and for the Year Ending March 31, 2020	CI
16/05/19	Sumitomo Bakelite Company Limited completed the acquisition of 20.8% stake in Kawasumi Laboratories, Incorporated.	CI
20/03/19	Sumitomo Bakelite Company Limited executed a capital and business alliance agreement to acquire 20.76% stake in Kawasumi Laboratories, Incorporated.	CI
10/08/18	Tranche Update on Kawasumi Laboratories, Incorporated's Equity Buyback Plan announced on August 9, 2018.	CI
10/08/18	Kawasumi Laboratories, Incorporated's Equity Buyback announced on August 9, 2018 has expired with 1,200,000 shares for ¥860.4 million.	CI
09/08/18	Kawasumi Laboratories, Incorporated announces an Equity Buyback for 1,300,000 shares, representing 5.96% for ¥932.1 million.	CI
09/08/18	Kawasumi Laboratories, Incorporated authorizes a Buyback Plan.	CI
15/05/18	Kawasumi Laboratories, Incorporated Announces Consolidated Earnings Results for the Year Ended March 31, 2018; Announces Dividend for the Year Ended March 31, 2018, Payable on June 22, 2018; Provides Earnings Guidance or the Year Ending March 31, 2019; Provides Dividend Guidance for the Second Quarter and Full Year Ending March 31, 2019	CI
08/02/18	Kawasumi Laboratories Inc. Announces Consolidated Earnings Results for the Nine Months Ended December 31, 2017; Provides Earnings and Dividend Guidance for the Year Ending March 31, 2018	CI
09/11/17	Kawasumi Laboratories Inc. Announces Consolidated Earnings Results for the Six Months Ended September 30, 2017; Provides Earnings Guidance for the Full Year of Fiscal Year Ending March 31, 2018	CI
23/10/17	Japanese Organization for Medical Device Development, Inc. announced that it has received ¥610 million in funding from Sumitomo Bakelite Company Limited, Kawasumi Laboratories, Incorporated	CI
09/08/17	Kawasumi Laboratories Inc. Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2017; Provides Earnings Guidance for the Six Months Ending September 30, 2017 and Full Year Ending March 31, 2018; Provides Second Quarter-End and Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2018	CI
11/05/17	Kawasumi Laboratories, Incorporated Announces Consolidated Earnings Results for the Year Ended March 31, 2017; Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2017 and Full Year Ending March 31, 2018; Announces Dividend for the Year Ended March 31, 2017, Payable on June 23, 2017; Provides Dividend Guidance for the Second Quarter of Fiscal 2018 and for the Year Ending March 31, 2018	CI
09/02/17	Kawasumi Laboratories Inc. Announces Consolidated Earnings Results for the nine Months Ended December 31, 2016; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2017; Provides Dividend Guidance for the Year End of Fiscal Year 2017	CI
10/11/16	Kawasumi Laboratories Inc. Announces Consolidated Earnings Results for the Six Months Ended September 30, 2016; Provides Consolidated Earnings Guidance for the Year Ending March 31, 2017; Announces Dividend for the Second Quarter End of Fiscal Year 2017, Payable on December 5, 2016; Provides Dividend Guidance for the Year End of Fiscal Year 2017	CI
10/08/16	Kawasumi Laboratories Inc. Announces Consolidated Earnings Results for the First Quarter Ended June 30, 2016; Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2016 and Full Year of Fiscal Year Ending March 31, 2017	CI
24/05/16	Kawasumi Laboratories Inc. Announces Consolidated Earnings Results for the Year Ended March 31, 2016; Declares Dividend for the Year Ended March 31, 2016, Payable on June 24, 2016; Provides Consolidated Earnings Guidance for the Six Months Ending September 30, 2016 and Full Year Ending March 31, 2017; Provides Dividend Guidance for the Year Ending March 31, 2017	CI
10/02/16	Tranche Update on Kawasumi Laboratories Inc.'s Equity Buyback Plan announced on November 11, 2015.	CI
10/02/16	Kawasumi Laboratories Inc. Announces Consolidated Earnings Results for the Third Quarter Ended December 2015	CI
09/02/16	Kawasumi Laboratories Inc.'s Equity Buyback announced on November 11, 2015, has expired with 1,051,400 shares, representing 4.6% for ¥999.95 million.	CI
03/02/16	Tranche Update on Kawasumi Laboratories Inc.'s Equity Buyback Plan announced on November 11, 2015.	CI
11/11/15	Kawasumi Laboratories Inc. authorizes a Buyback Plan.	CI
11/11/15	Kawasumi Laboratories Inc. announces an Equity Buyback for 1,200,000 shares, representing 5.25% for ¥1,000 million.	CI